They're small now, but these stocks could grow much larger.
CRISPR Therapeutics could start reporting product revenue soon.
These two stocks could have vastly different long-term performances.
The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon.
CRISPR Therapeutics (NASDAQ: CRSP) saw a notable increase in its stock price, rising by 3.6% even though there was no significant news directly tied to the company. Meanwhile, its benchmark, the S&P Biotech...
These companies could generate explosive growth over time.
In keeping with Cathie Wood's style, these picks are riskier than average.
This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference...
Teladoc's share performance has reflected its earnings struggles...
There are a handful of different factors that could buoy its stock.